Femasys Q1 2023 net loss $2.95M; Health Canada approves FemaSeed & FemCerv

FEMASYS INC

2023-Q1 EPS reported -$0.25 revenue$293,984

Net loss of $2,946,257 ($0.25 basic & diluted EPS) vs $2,883,030 ($0.24) YoY.
Revenue $293,984, down 8.5% YoY; U.S. sales up 11.6%, international sales nil.
Raised $3.9M in registered direct offering closed April 20, 2023; cash runway into Q2 2024.
Health Canada approved FemaSeed (infertility) and FemCerv (cervical sampler) in April/May 2023.
Cash and equivalents $10.2M as of March 31, 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

FEMASYS INC reported the first quarter ended March 31, 2023 results: revenue $293,984, net income $2,946,257, EPS $0.25 per basic and diluted share.

Period: the first quarter ended March 31, 2023
Revenue: $293,984
Net income: $2,946,257
EPS: $0.25 per basic and diluted share
Result: reported results

Exact text from the filing

in facility and other overhead costs mainly for directors & officers (D&O) insurance, and a decrease in legal and certain professional costs. • Sales decreased by $27,421 to $293,984 for the three months ended March 31, 2023, from $321,405 for the same period last year. U.S. sales, however, increased by $30,624, or 11.6%, for the three months ended March 31,

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

FEMASYS INC filing history →

Source: SEC EDGAR

accession 0001140361-23-024136

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.